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Abstract Background The GEMINI trials established the efficacy of vedolizumab in moderate-to-severe 
inflammatory bowel disease (IBD) and demonstrated a favorable safety profile, suggesting it may 
be advantageous in older patients at greater risk of treatment-related complications. However, 
there is a paucity of data exploring the outcomes of vedolizumab in this group. Our objective was 
to determine the clinical effectiveness and safety of vedolizumab in older IBD patients within a 
real-world multicenter UK cohort.
Methods A retrospective review of electronic records across 6 UK hospitals was undertaken to 
evaluate the clinical effectiveness and safety outcomes of vedolizumab in IBD patients aged ≥60 
at start of therapy. Rates of clinical response, remission and corticosteroid-free remission were 
assessed at weeks 14 and 52, using validated clinical indices, and were compared to historical 
controls from real-world vedolizumab-treated cohorts unstratified by age.
Results Of 74  patients aged 60  years or above (median 66  years), 48 were included in our 
effectiveness analysis (29 ulcerative colitis, 19 Crohn’s disease). Rates of clinical response, remission 
and corticosteroid-free remission at week 14 were 64%, 48% and 30%, respectively. By week 52, the 
rates of clinical response, remission, and corticosteroid-free remission were 52%, 38%, and 32%, 
respectively. Six (8%) patients experienced adverse effects. Effectiveness and safety outcomes were 
comparable to those of age-unstratified vedolizumab-treated cohorts.
Conclusion Our 1-year outcome data suggests that vedolizumab is safe and effective in older IBD 
patients and broadly comparable to cohorts unselected by age.
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and rising, with one Dutch population-based study reporting 
a 2-fold increase in incidence between 1991 and 2011 [2]. The 
majority of cases are diagnosed between 60-70  years, 25% 
between 70-80  years, and 10% over 80  years [3,4]. Several 
studies have highlighted differences in the disease trajectory 
of these patients compared with the younger population 
[5,6], with a suggestion that the natural history is less 
aggressive [6-9]. For example perianal and fistulizing disease 
occur less frequently in older onset IBD patients with Crohn’s 
disease (CD) [7]. Up to 30% of IBD patients are over 60 years 
old [8], and given the aging population and the small impact 
of IBD on mortality, the prevalence of IBD among the elderly 
is expected to increase.
Introduction
The incidence of older onset inflammatory bowel disease 
(IBD), typically defined as onset >60 years of age, is 10-15% [1] 
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Therapeutic options are theoretically the same in older 
and younger patients, but there are gaps in our understanding 
of the specific needs of the older group. Older patients are 
either excluded from or under-represented in clinical trials, 
hampering insights into the safety and efficacy of therapy as 
a function of age. Additional considerations that influence 
the optimal management strategy in this group include 
polypharmacy, multiple comorbidities, functional status and, 
crucially, adverse effects of therapy secondary to infection and 
malignancy. Safety data have consistently shown that advanced 
age is an independent risk factor for serious adverse events 
and death in patients treated with anti-tumor necrosis factor 
(TNF) medications [9,10], rendering older patients more likely 
to discontinue therapy [9,11]. In a Belgian retrospective study 
with 743 anti-TNF-treated patients, older age at first infusion 
was the only predictor of death (P<0.01) [12]. Older age is also 
an independent risk factor for lymphoproliferative disorders in 
thiopurine-treated patients; their incidence increases to more 
than 5-fold in the 50-65 age group, and even more in the >65 
group [13].
In terms of efficacy of biologic agents, older patients 
have lower rates of short-term clinical response to anti-
TNF therapy compared to younger patients, even after 
adjustment for confounding factors, although once an initial 
response is achieved they have a comparable long-term 
clinical response [9]. A similar pattern is observed from the 
rheumatology experience, which is based on  larger patient 
numbers and longer follow-up data [14].
The advent of vedolizumab, a gut-selective humanised 
monoclonal antibody targeting the a4b7 integrin expressed 
by gut-homing lymphocytes, represents an important advance 
in IBD therapy. The GEMINI trials demonstrated the clinical 
efficacy of vedolizumab for induction and maintenance of 
remission in moderate-to-severe active ulcerative colitis 
(UC) and CD, with a safety profile comparable to that of 
placebo [15,16]. Integrated safety data, from 2830  patients 
followed over 5  years, confirmed that vedolizumab was not 
associated with an increased risk of infection or malignancy. 
Moreover, infusion-related reactions, enteric infections and 
autoimmune events occurred infrequently [17]. Similarly, in a 
4-year post-marketing safety analysis based on 208,050 patient 
years of vedolizumab exposure, the rates of gastrointestinal 
and infection-related adverse events were comparable between 
patients aged ≥70 years and those <70 years [18].
Clinical and safety outcomes have been corroborated 
in observational studies of “real-world” practice [4,17,19-
25]. The gut-selective mechanism of action of vedolizumab 
is an especially attractive property in high-risk groups such 
as those with advanced age, or a history of malignancy or 
immunosuppression. However, there is a relative paucity of data 
in these groups. Yajnik et al conducted a post hoc analysis of 
the efficacy and safety of vedolizumab in GEMINI trial patients 
stratified by age, of whom 230  (130 UC, 90 CD) were in the 
>55 years group and 56 patients were aged >65 years. Efficacy 
(induction and maintenance) and safety profiles between 
vedolizumab and placebo were similar in all age groups, with no 
age-related differences in the incidence of malignancy or death 
[26]. Whilst these outcomes are promising, there are challenges 
in extrapolating data from clinical trials, given that they are 
highly selective and often exclude patients with significant 
comorbidities prevalent in the older population. We therefore 
aimed to determine the clinical effectiveness and safety of 
vedolizumab in older IBD patients in a multicenter UK cohort.
Patients and methods
This study included patients from 6 UK hospitals: Guy’s 
and St. Thomas’, King’s College, St. Mark’s, The Royal London, 
Addenbrooke’s, and The John Radcliffe. Older age was defined 
as ≥60  years. A  retrospective review of electronic records 
was performed to identify patients who started vedolizumab 
between January 2015 and 2018. Inclusion criteria were age 
≥60 and the availability of at least 12  months of follow-up 
data (irrespectively of whether vedolizumab was continued). 
Exclusion criteria for the clinical effectiveness analysis 
included clinically inactive disease at baseline, as defined using 
validated clinical indices—Harvey Bradshaw Index (HBI) 
for CD (HBI<5) or the Simple Clinical Colitis Activity Index 
(SCCAI) for UC (SCCAI<3)—missing baseline activity score 
data, and the presence of a stoma.
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Data collection was performed using a standardized form. 
Extracted data included demographics, baseline disease 
characteristics (subtype, disease duration, phenotype according 
to the Montreal classification for CD, history of surgery), 
baseline disease activity, history of malignancy, prior anti-TNF 
exposure, and concomitant immunomodulation. Patients with 
unclassified IBD were included in the UC group for analysis.
Effectiveness and safety data were extracted at week 14 
and week 52. Effectiveness measures were clinical response 
(reduction in HBI or SCCAI scores by ≥3 points), clinical 
remission (HBI<5 or SCCAI<3) and corticosteroid-free 
remission (HBI<5 or SCCAI<3 without concomitant 
steroids) [27,28]. An intention-to-treat strategy was used. 
Safety data included any adverse events. Where relevant, 
time to discontinuation of therapy was also collated alongside 
reasons for discontinuation.
Statistical analysis
Descriptive statistics were used to summarize differences in 
demographic and baseline characteristics among study groups. 
Continuous variables are presented as median and categorical 
variables are expressed as proportions. Data are presented to 
the nearest significant figure. The comparator groups were 
patients from previously published studies describing real-
world, observational experience of vedolizumab unstratified 
by age, identified via a structured PubMed and Embase search.
Results
Patient characteristics
During the study period, 74 patients aged ≥60 years received 
at least 1 dose of vedolizumab and had follow-up data for at 
least 1  year. Forty-eight patients were included in the clinical 
effectiveness analysis (Table 1). The other 26 were excluded for 
the following reasons: 3 had a stoma, 13 had missing clinical data 
for week 14 and week 52, 9 had inactive baseline clinical activity 
scores, and 1 had surgery very shortly after the first infusion. Of 
the 48 patients included, the median age on starting vedolizumab 
was 66 (range 60-85) years; 17  patients were in the ≥70 age 
group. Of these, 10 (21%) were between 70-79 years and 7 (15%) 
were aged ≥80. Seventeen patients (35%) had older-onset IBD. 
Analysis of adverse events was performed for all 74 patients who 
received at least 1 dose of vedolizumab (Table 2).
Table 1 Baseline characteristics of patients included in clinical effectiveness analysis (n=48)
Characteristic UC no. (%) CD no. (%) Total/overall no. (%)
IBD phenotype 29 (60) 19 (40) 48 (100)
Male sex 13 (69) 6 (27) 19 (40)
Median age (range) at time of starting vedolizumab 67 64 66 (60-85)
Older onset IBD 11 (38) 7 (37) 18 (38)
Median disease duration (range), years 8 11 9 (0-50)
Past medical history of malignancy 4 (14) 3 (16) 7 (15)
Corticosteroids at baseline 17 (59) 15 (79) 32 (67)













































UC, ulcerative colitis; CD, Crohn’s disease; IBD, inflammatory bowel disease; TNF, tumor necrosis factor
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Clinical effectiveness
In patients ≥60 years, 28  (64%) had a clinical response at 
week 14. Of these, 21 (48%) were in clinical remission (Table 3), a 
higher rate than those reported in the majority of observational 
studies from age-unstratified populations [19-21,23,24,29,30] 
(Fig.  1A,B). Thirty percent achieved corticosteroid-free 
remission (Fig.  1C). At week 52, 21  (81%) had a clinical 
response (Fig. 2A), 16 (62%) had clinical remission (Fig. 2B) 
and 13  (52%) had corticosteroid-free remission (Fig.  2C). 
These rates were relatively lower than those reported in the 
age-unstratified populations.
When taking into account disease type (UC vs. CD), the 
mean SCCAI scores in UC patients at baseline, week 14 and 
week 52 were 8 with a standard deviation (SD) of 3, 2 (SD 2) 
and 2 (SD 2), respectively. In CD patients, the mean HBI scores 
at baseline, week 14 and week 52 were 8 (SD 3), 5 (SD 3), and 
4 (SD 3), respectively.
UC patients were numerically more likely than CD 
patients to experience clinical response or remission 
at week 14  (76% vs. 47% and 60% vs. 32% respectively). 
Findings in the UC group were generally more favorable 
than most of the age-unstratified comparator studies 
where rates of clinical response and remission ranged 
between 43%-57% (UC), whilst findings in the CD group 
were more comparable (22-42%) (Supplementary Fig.  1). 
At week 52, rates of clinical response, clinical remission 
and steroid-free remission were comparable between UC 
and CD patients (52% vs. 53%, 40% vs. 35%, 33% vs. 29%, 
respectively (Supplementary Fig. 2).
Safety
Adverse events were reported in 6/74  (8%) patients, 
leading to permanent discontinuation in 4/6 (Table 4). Three 
of these 6 patients were on concomitant immunosuppressive 
treatment: 1 with relapsed chronic myelomonocytic leukemia 
(CMML) on mycophenolate mofetil and prednisolone, 1 with 
pneumonia requiring intensive care support on azathioprine, 
and 1 with Escherichia coli O157 on azathioprine. Of the 
3/6  patients on vedolizumab monotherapy, 2 experienced 
arthralgia necessitating permanent discontinuation of therapy 
after 1 and 5 months, and 1 patient-developed deranged liver 
function tests, which resolved on cessation of treatment. 
According to age, 4/6 were in the 60-69 group and 2 were 
Table 2 Baseline characteristics of patients included in safety analysis (n=74)
Characteristic UC no. (%) CD no. (%) Total/overall no. (%)
IBD phenotype 44 (59) 30 (41) 74 (100)
Male sex 19 (43) 9(30) 28 (38)
Median age (range) at time of starting vedolizumab 68 65 67 (60-85)
Median disease duration (range), years 9 14 11 (0-50)
Older onset IBD 18(41) 9(30) 20(27)
Past medical history of malignancy 7 (16) 6 (20) 13 (18)
Corticosteroids at baseline 29 (66) 12 (40) 41 (55)













































UC, ulcerative colitis; CD, Crohn’s disease; IBD, inflammatory bowel disease; TNF, tumor necrosis factor
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aged ≥70  years. There were no reported infusion reactions. 
One death occurred during the study period: a patient with 
relapsed CMML who had 8 months of vedolizumab therapy 
prior to the diagnosis.
Discussion
Our study represents the largest cohort of older vedolizumab-
treated patients reported to date and represents a real-world 
Table 3 Clinical effectiveness of vedolizumab in patients aged ≥60 years (n=48)
Variable Ulcerative colitis no. (%) Crohn’s disease no. (%) Total/overall no. (%)
Inflammatory bowel disease phenotype 29 (60) 19 (40) 48(100)
Corticosteroids at week 0 21 (72) 11 (58) 32 (67)
Corticosteroids at week 14 12 (41) 5 (26) 17 (35)
Corticosteroids at week 52† 7 (28) 1 (7) 8 (23)
Clinical response week 14‡ 19 (76) 9 (47) 28 (64)
Clinical remission week 14‡ 15 (60) 6 (32) 21 (48)
Corticosteroid-free remission week 14§ 9 (32) 5 (26) 14 (30)
Clinical response week 52¶ 13 (52) 9 (53) 22 (52)
Clinical remission week 52¶ 10 (40) 6 (35) 16 (38)
Corticosteroid-free remission week 52 8 (33) 5 (29) 13 (32)
Rate of surgery 3 (10) 5 (26) 8 (17)
Number completing 54 weeks of vedolizumab 20 (69) 14 (74) 34 (71)
Adverse event 2 (7) 0 2 (4)*
Primary non-responder 2 (7) 0 2 (42)
Loss of response 3 (10) 0 3 (6)
Data available for †n=35, ‡n=44, §n=47, ¶n=42, n=41























































































































Figure 1 Week 14 clinical response (A), clinical remission (B) and corticosteroid-free remission rates (C) in patients with inflammatory bowel 
disease, comparing those aged ≥60 in our UK multicenter cohort with a non-age-stratified real-world series. The pooled data bar only represents 
studies from the age-unstratified real-world studies. Error bars represent ± 1 standard deviation. The age is represented on the X-axis as a median 
or mean. In some studies, the median or mean age was calculated for each subgroup (Crohn’s disease vs. ulcerative colitis) and not a group as a 
whole: in these cases both numbers are depicted
C
BA
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context for its use. Although randomized controlled trials 
represent the gold standard for establishing efficacy, patients 
are highly selected and not entirely representative of those 
encountered in clinical practice. Notably, 44% of our patients 
would have been excluded from the GEMINI studies because 
of concomitant medications, extensive CD surgery, and older 
age. Whilst the GEMINI trials included older patients, those 
over 80 were excluded. Our study included 7  patients over 
80 years, 2 of whom were on concomitant thiopurine therapy 
while 3 had a past history of malignancy.
We report outcomes largely comparable to the majority 
of the age-unstratified observational studies, although 
interestingly we found more favorable week-14 outcomes. This 
may be attributed to a cohort that included a higher proportion 
of anti-TNF-naïve patients (73% compared to fewer than 
25% in comparator studies), given how closely our findings 
resemble those from the European study in anti-TNF-naïve 
patients [25]. Additionally, over a third of our study group had 
older-onset IBD, ostensibly associated with a less aggressive 
disease course [5]. These merit further investigation, but 
to date, Navaneethan et al are the only group to report real-
world clinical outcomes of vedolizumab-treated older patients 
(>60  years old) [31]. In their single-center study, which 
included 29 IBD patients, clinical response and remission rates 
Table 4 Safety of vedolizumab in patients ≥60 years (n=74)
Age Disease AE AE leading to treatment 
suspension or permanent 
discontinuation
Duration of therapy 




66 CD Relapsed chronic 
myelomonocytic leukemia
Yes, discontinued 8 Mycophenolate mofetil 
and prednisolone
70 CD Arthralgia Yes, discontinued 5 Nil
61 UC Arthralgia Yes, discontinued 1 Nil
77 UC Deranged liver function tests Yes, discontinued 7 Nil
65 UC Escherichia coli O157 
gastroenteritis
No 5 Azathioprine
62 UC Pneumonia necessitating ICU 
admission
Yes, suspended for 2 
months
10 Azathioprine




















































































Figure 2 Week 52 clinical response (A), clinical remission (B) and corticosteroid-free remission rates (C) in patients with inflammatory bowel 
disease, comparing those aged ≥60 in our UK multicenter cohort with a non-age-stratified real-world series. The pooled data bar only represents 
studies from the age-unstratified real-world studies. Error bars represent ± 1 standard deviation. The age is represented on the X-axis as a median 
or mean. In some studies, the median or mean age was calculated for each subgroup (Crohn’s disease vs. ulcerative colitis) and not a group as a 
whole: in these cases both numbers are depicted
C
BA
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were lower than in our group (Fig.  1,2). Corticosteroid-free 
remission was only reported for week 14, but was similar to our 
data. Although caution should be exercised when interpreting 
studies with small patient numbers, an important difference 
again relates to the lower proportion of anti-TNF-experienced 
patients included in our study (27% vs. 68.9%).
Yajnik et al performed a post hoc subgroup analysis of data 
from GEMINI 1 and 2, which analyzed moderately to severely 
active UC or CD, respectively, stratified into age groups: <35, 
35 to <55, and ≥55  years. Two hundred and twenty patients 
(130 UC, 90 CD) were in the older group, and apart from 
having a longer duration of disease, and the CD patients having 
lower clinical activity scores at baseline, other baseline features 
were consistent amongst the groups. Similar percentages of 
vedolizumab-treated patients from each age group achieved a 
durable clinical response, durable clinical remission, mucosal 
healing, and corticosteroid-free remission at week 52, with no 
age-related trends [26].
Despite 42% of our patients being on an immunomodulator 
(compared to a range of 14-80.4% in the non-age-stratified real 
world studies), we, like others [21], did not observe a larger 
clinical benefit compared with vedolizumab monotherapy. 
Although our sample size may be too small to detect a 
difference, this finding was also apparent from a post hoc 
analysis of the pivotal trials, where the use of concomitant 
immunomodulators was 18.9% in GEMINI 1 and 16.1% in 
GEMINI 2 [15,16].
Consistent with the post hoc and post-marketing analyses, 
we found that the safety profile of vedolizumab in older 
patients was favorable [17,18]. The adverse event rate of 8% is 
comparable to other real-world series, where rates of 8.2% [19], 
10.7% [21], and 14.2% [23] were reported. The 3  patients 
who developed either a serious infection or recurrence of 
malignancy were also on concomitant immunomodulators, 
which have a well-documented association with these 
outcomes. Two patients discontinued therapy secondary to 
arthralgia.
Limitations of our study include a lack of endoscopic 
data and a limited cohort size (particularly the CD group), 
which made subgroup analyses challenging. The majority of 
patients were on corticosteroids at baseline, thus introducing 
a confounding variable that may have influenced the perceived 
effectiveness of vedolizumab in the short term. Additionally, 
the risk of infective events associated with corticosteroids is 
well documented. The retrospective nature of the data may 
also have resulted in an underestimation of the number of 
adverse events. However, such biases are inevitable features 
of real-world studies and are therefore not dissimilar to other 
published real-world series.
In conclusion, our multicenter experience of vedolizumab 
in IBD patients aged 60 or older demonstrated that treatment 
was effective and well-tolerated at 1  year, and likely to be 
broadly comparable to cohorts unselected by age. Given the 
absence of prospective controlled studies of vedolizumab in 
elderly patients, our study provides reassuring insights into 
the potential benefit of vedolizumab as an effective and safe 
therapeutic option in this patient group.
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Supplementary Figure 1 Week 14 clinical response, clinical remission and corticosteroid-free remission rates in patients with ulcerative colitis (A) 
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Supplementary Figure 2 Week 52 clinical response, clinical remission and corticosteroid-free remission rates in patients with ulcerative colitis (A) 
and Crohn’s disease (B), comparing those aged ≥60 in our UK multicenter cohort with a non-age-stratified real-world series
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